Published in Lancet Infect Dis on March 19, 2012
Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda | NCT00405821
Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy. J Infect Dis (2013) 1.02
Integrating prevention interventions for people living with HIV into care and treatment programs: a systematic review of the evidence. J Acquir Immune Defic Syndr (2015) 1.00
Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial. J Infect Dis (2013) 0.89
Vaginal Cytomegalovirus Shedding Before and After Initiation of Antiretroviral Therapy in Rakai, Uganda. J Infect Dis (2015) 0.86
Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2. PLoS One (2012) 0.85
Herpes simplex virus type 2 and HIV disease progression: a systematic review of observational studies. BMC Infect Dis (2013) 0.85
High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial. J Acquir Immune Defic Syndr (2013) 0.83
Medical male circumcision and herpes simplex virus 2 acquisition: posttrial surveillance in Kisumu, Kenya. J Infect Dis (2013) 0.83
The Role of Sexually Transmitted Infections in HIV-1 Progression: A Comprehensive Review of the Literature. J Sex Transm Dis (2013) 0.83
Hypertension, cardiovascular risk factors and antihypertensive medication utilisation among HIV-infected individuals in Rakai, Uganda. Trop Med Int Health (2014) 0.83
Antiretroviral therapy is not associated with reduced herpes simplex virus shedding in HIV coinfected adults: an observational cohort study. BMJ Open (2014) 0.82
Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females. Int J Womens Health (2012) 0.81
HIV infection and immune activation: the role of coinfections. Curr Opin HIV AIDS (2016) 0.81
Human Herpesviruses as Copathogens of HIV Infection, Their Role in HIV Transmission, and Disease Progression. J Lab Physicians (2016) 0.81
A transmission-virulence evolutionary trade-off explains attenuation of HIV-1 in Uganda. Elife (2016) 0.81
Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. Clin Microbiol Rev (2016) 0.80
Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial. Clin Infect Dis (2015) 0.80
Brief report: HIV-1 transmissions during asymptomatic infection: exploring the impact of changes in HIV-1 viral load due to coinfections. J Acquir Immune Defic Syndr (2015) 0.79
Immunological Signaling During Herpes Simplex Virus-2 and Cytomegalovirus Vaginal Shedding After Initiation of Antiretroviral Treatment. Open Forum Infect Dis (2016) 0.78
Frequent detection of HPV before and after initiation of antiretroviral therapy among HIV/HSV-2 co-infected women in Uganda. PLoS One (2013) 0.77
Aciclovir for dual infection with HIV and HSV. Lancet Infect Dis (2012) 0.75
Precision of the Kalon Herpes Simplex Virus Type 2 IgG ELISA: an international inter-laboratory assessment. BMC Infect Dis (2015) 0.75
Reporting of pre-enrolment screening with randomized clinical trials: A small item that could impact a big difference. Perspect Clin Res (2015) 0.75
Elevated cytomegalovirus IgG antibody levels are associated with HIV-1 disease progression and immune activation. AIDS (2017) 0.75
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 18.38
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 9.17
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ (2008) 3.62
Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans. J Clin Microbiol (2004) 3.36
Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis (2000) 3.21
Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA (1998) 3.03
Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe (2008) 3.02
Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS (2008) 2.91
Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis (2003) 2.72
The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis (1997) 2.31
Herpes simplex virus type 2 (HSV-2) Western blot confirmatory testing among men testing positive for HSV-2 using the focus enzyme-linked immunosorbent assay in a sexually transmitted disease clinic. Sex Transm Dis (2005) 1.91
The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology (1994) 1.85
Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. JAMA (1988) 1.76
Association between cervical shedding of herpes simplex virus and HIV-1. AIDS (2002) 1.64
The biochemistry and mechanism of action of acyclovir. J Antimicrob Chemother (1983) 1.41
Diminishing availability of publicly funded slots for antiretroviral initiation among HIV-infected ART-eligible patients in Uganda. PLoS One (2010) 1.35
Herpes simplex virus infection induces replication of human immunodeficiency virus type 1. Virology (2000) 1.23
Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study). J Acquir Immune Defic Syndr (2011) 1.20
High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial. J Infect Dis (2011) 1.09
Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation. Biostatistics (2005) 1.07
Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons. J Infect Dis (2011) 1.04
Mechanisms associated with HIV-1 resistance to acyclovir by the V75I mutation in reverse transcriptase. J Biol Chem (2009) 0.98
Health professionals for a new century: transforming education to strengthen health systems in an interdependent world. Lancet (2010) 42.10
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet (2007) 37.69
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
Laboratory medicine in Africa: a barrier to effective health care. Clin Infect Dis (2005) 12.59
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med (2009) 8.26
Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet (2009) 6.80
Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS (2007) 5.97
The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr (2004) 5.94
Untreated gonococcal and chlamydial infection in a probability sample of adults. JAMA (2002) 5.07
Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS (2009) 4.54
Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet (2005) 4.51
Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis (2008) 4.48
Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis (2013) 4.27
HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS (2011) 4.26
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA (2005) 4.24
The medical benefits of male circumcision. JAMA (2011) 4.05
Male circumcision for the prevention of acquisition and transmission of sexually transmitted infections: the case for neonatal circumcision. Arch Pediatr Adolesc Med (2010) 3.84
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. Am J Obstet Gynecol (2008) 3.60
Incident HIV and herpes simplex virus type 2 infection among men in Rakai, Uganda. AIDS (2009) 3.53
Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet (2011) 3.52
Domestic violence in rural Uganda: evidence from a community-based study. Bull World Health Organ (2003) 3.45
Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study. BMJ (2007) 3.41
Voluntary HIV counseling and testing acceptance, sexual risk behavior and HIV incidence in Rakai, Uganda. AIDS (2005) 3.39
Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans. J Clin Microbiol (2004) 3.36
The history and challenge of HIV prevention. Lancet (2008) 3.34
Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30
Age differences in sexual partners and risk of HIV-1 infection in rural Uganda. J Acquir Immune Defic Syndr (2003) 3.11
Child mortality associated with reasons for non-breastfeeding and weaning: is breastfeeding best for HIV-positive mothers? AIDS (2003) 3.00
Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis (2005) 3.00
The contribution of HIV-discordant relationships to new HIV infections in Rakai, Uganda. AIDS (2011) 2.94
A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. Lancet Infect Dis (2006) 2.92
The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. AIDS (2012) 2.92
Reassessing the hypothesis on STI control for HIV prevention. Lancet (2008) 2.82
The safety of adult male circumcision in HIV-infected and uninfected men in Rakai, Uganda. PLoS Med (2008) 2.79
Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol (2003) 2.78
Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet (2008) 2.75
Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis (2003) 2.72
Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis (2010) 2.70
Mortality in HIV-infected and uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquir Immune Defic Syndr (2006) 2.66
Two-year virologic outcomes of an alternative AIDS care model: evaluation of a peer health worker and nurse-staffed community-based program in Uganda. J Acquir Immune Defic Syndr (2009) 2.62
Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS (2003) 2.60